|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
2
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar :
|
|
3
|
Sher T, Dy GK and Adjei AA: Small cell
lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar
|
|
4
|
Shtivelman E, Hensing T, Simon GR, Dennis
PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and
therapeutic targets in lung cancer. Oncotarget. 5:1392–1433. 2014.
View Article : Google Scholar :
|
|
5
|
Schnabel PA and Junker K: Neuroendocrine
tumors of the lungs. From small cell lung carcinoma to diffuse
idiopathic pulmonary neuroendocrine cell hyperplasia. Pathologe.
35:557–564. 2014.(In German). View Article : Google Scholar
|
|
6
|
Harley VR, Clarkson MJ and Argentaro A:
The molecular action and regulation of the testis-determining
factors, SRY (sex-determining region on the Y chromosome) and SOX9
SRY-related high-mobility group (HMG) box 9. Endocr Rev.
24:466–487. 2003. View Article : Google Scholar
|
|
7
|
Wagner T, Wirth J, Meyer J, Zabel B, Held
M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, et al:
Autosomal sex reversal and campomelic dysplasia are caused by
mutations in and around the SRY-related gene SOX9. Cell.
79:1111–1120. 1994. View Article : Google Scholar
|
|
8
|
Foster JW, Dominguez-Steglich MA, Guioli
S, Kwok C, Weller PA, Stevanović M, Weissenbach J, Mansour S, Young
ID, Goodfellow PN, et al: Campomelic dysplasia and autosomal sex
reversal caused by mutations in an SRY-related gene. Nature.
372:525–530. 1994. View
Article : Google Scholar
|
|
9
|
Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu
XY and Gong LY: Clinical significance of SOX9 in human non-small
cell lung cancer progression and overall patient survival. J Exp
Clin Cancer Res. 31:182012. View Article : Google Scholar :
|
|
10
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar :
|
|
11
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar
|
|
12
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar
|
|
14
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar
|
|
15
|
Skrzypski M, Dziadziuszko R and Jassem J:
MicroRNA in lung cancer diagnostics and treatment. Mutat Res.
717:25–31. 2011. View Article : Google Scholar
|
|
16
|
Boeri M, Sestini S, Fortunato O, Verri C,
Suatoni P, Pastorino U and Sozzi G: Recent advances of
microRNA-based molecular diagnostics to reduce false-positive lung
cancer imaging. Expert Rev Mol Diagn. 15:801–813. 2015.
|
|
17
|
Guan P, Yin Z, Li X, Wu W and Zhou B:
Meta-analysis of human lung cancer microRNA expression profiling
studies comparing cancer tissues with normal tissues. J Exp Clin
Cancer Res. 31:542012. View Article : Google Scholar :
|
|
18
|
Li Z, Li B, Niu L and Ge L: miR-592
functions as a tumor suppressor in human non-small cell lung cancer
by targeting SOX9. Oncol Rep. 37:297–304. 2017. View Article : Google Scholar
|
|
19
|
Wang X, Liu Y, Liu X, Yang J, Teng G,
Zhang L and Zhou C: MiR-124 inhibits cell proliferation, migration
and invasion by directly targeting SOX9 in lung adenocarcinoma.
Oncol Rep. 35:3115–3121. 2016. View Article : Google Scholar
|
|
20
|
Miranda KC, Huynh T, Tay Y, Ang YS, Tam
WL, Thomson AM, Lim B and Rigoutsos I: A pattern-based method for
the identification of MicroRNA binding sites and their
corresponding heteroduplexes. Cell. 126:1203–1217. 2006. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Ikeda K, Satoh M, Pauley KM, Fritzler MJ,
Reeves WH and Chan EK: Detection of the argonaute protein Ago2 and
microRNAs in the RNA induced silencing complex (RISC) using a
monoclonal antibody. J Immunol Methods. 317:38–44. 2006. View Article : Google Scholar :
|
|
23
|
Belo J, Krishnamurthy M, Oakie A and Wang
R: The role of SOX9 transcription factor in pancreatic and duodenal
development. Stem Cells Dev. 22:2935–2943. 2013. View Article : Google Scholar
|
|
24
|
Ma F, Ye H, He HH, Gerrin SJ, Chen S,
Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, et al: SOX9 drives
WNT pathway activation in prostate cancer. J Clin Invest.
126:1745–1758. 2016. View
Article : Google Scholar :
|
|
25
|
Zhu D, Chen H, Yang X, Chen W, Wang L, Xu
J and Yu L: miR-32 functions as a tumor suppressor and directly
targets SOX9 in human non-small cell lung cancer. Onco Targets
Ther. 8:1773–1783. 2015. View Article : Google Scholar :
|
|
26
|
Zhang YJ, Xu F, Li HB, Han JC and Li L:
miR-206 inhibits non small cell lung cancer cell proliferation and
invasion by targeting SOX9. Int J Clin Exp Med. 8:9107–9113.
2015.
|
|
27
|
Xie C, Han Y, Liu Y, Han L and Liu J:
miRNA-124 down-regulates SOX8 expression and suppresses cell
proliferation in non-small cell lung cancer. Int J Clin Exp Pathol.
7:6534–6542. 2014.
|
|
28
|
Zu L, Xue Y and Wang J, Fu Y, Wang X, Xiao
G, Hao M, Sun X, Wang Y, Fu G and Wang J: The feedback loop between
miR-124 and TGF-β pathway plays a significant role in non-small
cell lung cancer metastasis. Carcinogenesis. 37:333–343. 2016.
View Article : Google Scholar
|
|
29
|
Qiu F, Xiong JP, Deng J and Xiang XJ:
TRIM29 functions as an oncogene in gastric cancer and is regulated
by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.
|
|
30
|
Tan Z, Jiang H, Wu Y, Xie L, Dai W, Tang H
and Tang S: miR-185 is an independent prognosis factor and
suppresses tumor metastasis in gastric cancer. Mol Cell Biochem.
386:223–231. 2014. View Article : Google Scholar
|
|
31
|
Zou Q, Wu H, Fu F, Yi W, Pei L and Zhou M:
RKIP suppresses the proliferation and metastasis of breast cancer
cell lines through up-regulation of miR-185 targeting HMGA2. Arch
Biochem Biophys. 610:25–32. 2016. View Article : Google Scholar
|
|
32
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce
cell cycle arrest in human non small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar :
|
|
33
|
Li S, Ma Y, Hou X, Liu Y, Li K, Xu S and
Wang J: MiR-185 acts as a tumor suppressor by targeting AKT1 in
non-small cell lung cancer cells. Int J Clin Exp Pathol.
8:11854–11862. 2015.
|
|
34
|
Tang H, Liu P, Yang L and Xie X, Ye F, Wu
M, Liu X, Chen B, Zhang L and Xie X: miR-185 suppresses tumor
proliferation by directly targeting E2F6 and DNMT1 and indirectly
upregulating BRCA1 in triple-negative breast cancer. Mol Cancer
Ther. 13:3185–3197. 2014. View Article : Google Scholar
|
|
35
|
Pei K, Zhu JJ, Wang CE, Xie QL and Guo JY:
MicroRNA-185-5p modulates chemosensitivity of human non-small cell
lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol
Sci. 20:4697–4704. 2016.
|
|
36
|
Santos JC, Carrasco-Garcia E, Garcia-Puga
M, Aldaz P, Montes M, Fernandez-Reyes M, de Oliveira CC, Lawrie CH,
Araúzo-Bravo MJ, Ribeiro ML and Matheu A: SOX9 elevation acts with
canonical WNT signaling to drive gastric cancer progression. Cancer
Res. 76:6735–6746. 2016. View Article : Google Scholar
|
|
37
|
Liu H, Liu Z, Jiang B, Peng R, Ma Z and Lu
J: SSOX9 overexpression promotes Glioma metastasis via
Wnt/β-catenin signaling. Cell Biochem Biophys. 73:205–212. 2015.
View Article : Google Scholar
|
|
38
|
Wu KF, Liang WC, Feng L, Pang JX, Waye MM,
Zhang JF and Fu WM: H19 mediates methotrexate resistance in
colorectal cancer through activating Wnt/β-catenin pathway. Exp
Cell Res. 350:312–317. 2017. View Article : Google Scholar
|
